Ada C Stefanescu Schmidt1, Dean J Kereiakes1, Donald E Cutlip1, Robert W Yeh1, Ralph B D'Agostino1, Joseph M Massaro1, Wen-Hua Hsieh1, Laura Mauri2. 1. From Massachusetts General Hospital, Boston (A.C.S.S.); Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute), Boston, MA (A.C.S.S., D.E.C., R.W.Y., R.B.D'A., J.M.M., W.-H.H., L.M.); Brigham and Women's Hospital, Boston, MA (A.C.S.S., L.M.); Christ Hospital, Heart and Vascular Center and Lindner Center for Research and Education, Cincinnati, OH (D.J.K.); and Beth Israel Deaconess Medical Center, Boston, MA (D.E.C., R.W.Y.). 2. From Massachusetts General Hospital, Boston (A.C.S.S.); Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute), Boston, MA (A.C.S.S., D.E.C., R.W.Y., R.B.D'A., J.M.M., W.-H.H., L.M.); Brigham and Women's Hospital, Boston, MA (A.C.S.S., L.M.); Christ Hospital, Heart and Vascular Center and Lindner Center for Research and Education, Cincinnati, OH (D.J.K.); and Beth Israel Deaconess Medical Center, Boston, MA (D.E.C., R.W.Y.). lmauri1@partners.org.
Abstract
BACKGROUND:Thienopyridine plus aspirin beyond 1 year after coronary stenting reduces myocardial infarction (MI) risk and increases bleeding risk in comparison with aspirin alone. The hazard associated with late thienopyridine discontinuation and risk factors for MI after discontinuation are poorly defined. METHODS: In the DAPT Study (Dual Antiplatelet Therapy), after percutaneous coronary intervention and 12 months of thienopyridine (clopidogrel or prasugrel) plus aspirin, eligible patients remained on aspirin and were randomly assigned to continued thienopyridine versus placebo for 18 months. At 30 months, patients stopped the study drug and were observed for 3 months. Cumulative incidence of MI was assessed over 3 months after randomization (months 12-15) and 3 months after study drug discontinuation (months 30-33). The MI hazard for each of these periods was assessed across randomized treatment arms and by DAPT score values <2 or ≥2. RESULTS: Among the 11 648 randomly assigned patients, the monthly cumulative incidence of MI was lower with continued thienopyridine versus placebo at 12 to 15 months (0.12% versus 0.37%, P<0.001, in all patients; 0.13% versus 0.27%, P=0.02, in patients not treated with paclitaxel-eluting stents), and higher at 30 to 33 months (0.30% versus 0.15%, P=0.013, in all patients; in patients without paclitaxel-eluting stents, 0.18% versus 0.17%, P=0.91). The majority of MIs in both time periods (74% and 76%) were not related to stent thrombosis. After multivariable adjustment, treatment arm independently predicted MI at months 12 to 15 (P<0.001) and 30 to 33 (P=0.011). During months 12 to 15, patients with DAPT scores <2 or ≥2 both had lower rates of MI with continued thienopyridine (MI monthly incidence 0.16% versus 0.51%, P<0.001, for scores ≥2; 0.08% versus 0.24%, P=0.012, for scores<2, interaction P=0.064). CONCLUSIONS:Discontinuing thienopyridine after either 12 or 30 months is associated with an early increase in MI risk, mainly unrelated to stent thrombosis; the magnitude of risk is highest in the earlier time frame, and lower in patients not treated with paclitaxel-eluting stents. Although higher DAPT scores identify patients with greater absolute ischemic benefit (relative to bleeding harm) with continued thienopyridine therapy, discontinuation at 12 months increases MI hazard regardless of DAPT score group. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00977938.
RCT Entities:
BACKGROUND:Thienopyridine plus aspirin beyond 1 year after coronary stenting reduces myocardial infarction (MI) risk and increases bleeding risk in comparison with aspirin alone. The hazard associated with late thienopyridine discontinuation and risk factors for MI after discontinuation are poorly defined. METHODS: In the DAPT Study (Dual Antiplatelet Therapy), after percutaneous coronary intervention and 12 months of thienopyridine (clopidogrel or prasugrel) plus aspirin, eligible patients remained on aspirin and were randomly assigned to continued thienopyridine versus placebo for 18 months. At 30 months, patients stopped the study drug and were observed for 3 months. Cumulative incidence of MI was assessed over 3 months after randomization (months 12-15) and 3 months after study drug discontinuation (months 30-33). The MI hazard for each of these periods was assessed across randomized treatment arms and by DAPT score values <2 or ≥2. RESULTS: Among the 11 648 randomly assigned patients, the monthly cumulative incidence of MI was lower with continued thienopyridine versus placebo at 12 to 15 months (0.12% versus 0.37%, P<0.001, in all patients; 0.13% versus 0.27%, P=0.02, in patients not treated with paclitaxel-eluting stents), and higher at 30 to 33 months (0.30% versus 0.15%, P=0.013, in all patients; in patients without paclitaxel-eluting stents, 0.18% versus 0.17%, P=0.91). The majority of MIs in both time periods (74% and 76%) were not related to stent thrombosis. After multivariable adjustment, treatment arm independently predicted MI at months 12 to 15 (P<0.001) and 30 to 33 (P=0.011). During months 12 to 15, patients with DAPT scores <2 or ≥2 both had lower rates of MI with continued thienopyridine (MI monthly incidence 0.16% versus 0.51%, P<0.001, for scores ≥2; 0.08% versus 0.24%, P=0.012, for scores<2, interaction P=0.064). CONCLUSIONS: Discontinuing thienopyridine after either 12 or 30 months is associated with an early increase in MI risk, mainly unrelated to stent thrombosis; the magnitude of risk is highest in the earlier time frame, and lower in patients not treated with paclitaxel-eluting stents. Although higher DAPT scores identify patients with greater absolute ischemic benefit (relative to bleeding harm) with continued thienopyridine therapy, discontinuation at 12 months increases MI hazard regardless of DAPT score group. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00977938.
Authors: Kirk N Garratt; David P Lee; Eileen M Rose; Kellie J Windle; Hsini Liao; Chuke E Nwachuku; Kenneth J Winters; Thomas S Bowman; Keith D Dawkins Journal: Am Heart J Date: 2012-02 Impact factor: 4.749
Authors: Glenn N Levine; Eric R Bates; John A Bittl; Ralph G Brindis; Stephan D Fihn; Lee A Fleisher; Christopher B Granger; Richard A Lange; Michael J Mack; Laura Mauri; Roxana Mehran; Debabrata Mukherjee; L Kristin Newby; Patrick T O'Gara; Marc S Sabatine; Peter K Smith; Sidney C Smith Journal: Circulation Date: 2016-03-29 Impact factor: 29.690
Authors: Dean J Kereiakes; Robert W Yeh; Joseph M Massaro; Priscilla Driscoll-Shempp; Donald E Cutlip; P Gabriel Steg; Anthony H Gershlick; Harald Darius; Ian T Meredith; John Ormiston; Jean Francois Tanguay; Stephan Windecker; Kirk N Garratt; David E Kandzari; David P Lee; Daniel I Simon; Adrian Corneliu Iancu; Jaroslaw Trebacz; Laura Mauri Journal: JAMA Date: 2015-03-17 Impact factor: 56.272
Authors: Kirk N Garratt; W Douglas Weaver; Ronald G Jenkins; Thomas K Pow; Laura Mauri; Dean J Kereiakes; Kenneth J Winters; Thomas Christen; Dominic J Allocco; David P Lee Journal: Circulation Date: 2014-11-16 Impact factor: 29.690
Authors: Roxana Mehran; Usman Baber; Philippe Gabriel Steg; Cono Ariti; Giora Weisz; Bernhard Witzenbichler; Timothy D Henry; Annapoorna S Kini; Thomas Stuckey; David J Cohen; Peter B Berger; Ioannis Iakovou; George Dangas; Ron Waksman; David Antoniucci; Samantha Sartori; Mitchell W Krucoff; James B Hermiller; Fayaz Shawl; C Michael Gibson; Alaide Chieffo; Maria Alu; David J Moliterno; Antonio Colombo; Stuart Pocock Journal: Lancet Date: 2013-09-01 Impact factor: 79.321
Authors: Martine Gilard; Paul Barragan; Arif A L Noryani; Hussam A Noor; Talib Majwal; Thomas Hovasse; Philippe Castellant; Michel Schneeberger; Luc Maillard; Erwan Bressolette; Jaroslaw Wojcik; Nicolas Delarche; Didier Blanchard; Bernard Jouve; Olivier Ormezzano; Franck Paganelli; Gilles Levy; Joël Sainsous; Didier Carrie; Alain Furber; Jacques Berland; Oliver Darremont; Hervé Le Breton; Anne Lyuycx-Bore; Antoine Gommeaux; Claude Cassat; Alain Kermarrec; Pierre Cazaux; Philippe Druelles; Raphael Dauphin; Jean Armengaud; Patrick Dupouy; Didier Champagnac; Patrick Ohlmann; Knut Endresen; Hakim Benamer; Robert Gabor Kiss; Imre Ungi; Jacques Boschat; Marie-Claude Morice Journal: J Am Coll Cardiol Date: 2014-11-16 Impact factor: 24.094
Authors: Marc P Bonaca; Deepak L Bhatt; Marc Cohen; Philippe Gabriel Steg; Robert F Storey; Eva C Jensen; Giulia Magnani; Sameer Bansilal; M Polly Fish; Kyungah Im; Olof Bengtsson; Ton Oude Ophuis; Andrzej Budaj; Pierre Theroux; Mikhail Ruda; Christian Hamm; Shinya Goto; Jindrich Spinar; José Carlos Nicolau; Robert G Kiss; Sabina A Murphy; Stephen D Wiviott; Peter Held; Eugene Braunwald; Marc S Sabatine Journal: N Engl J Med Date: 2015-03-14 Impact factor: 91.245
Authors: Dean J Kereiakes; Robert W Yeh; Joseph M Massaro; Priscilla Driscoll-Shempp; Donald E Cutlip; P Gabriel Steg; Anthony H Gershlick; Harald Darius; Ian T Meredith; John Ormiston; Jean-François Tanguay; Stephan Windecker; Kirk N Garratt; David E Kandzari; David P Lee; Daniel I Simon; Adrian Corneliu Iancu; Jaroslaw Trebacz; Laura Mauri Journal: JACC Cardiovasc Interv Date: 2015-10 Impact factor: 11.195
Authors: P Michael Ho; Eric D Peterson; Li Wang; David J Magid; Stephan D Fihn; Greg C Larsen; Robert A Jesse; John S Rumsfeld Journal: JAMA Date: 2008-02-06 Impact factor: 56.272